

June 17, 2021

FILED VIA SEDAR

**Canadian Securities Exchange
British Columbia Securities Commission
Alberta Securities Commission**

Dear Sirs/Mesdames:

Re: Egret Biosciences Inc. (the "Company")

We refer to the non-offering prospectus (the "Prospectus") dated June 17, 2021 relating to the listing of Lexston Life Sciences Corp. ("Lexston") to become a reporting issuer in the provinces of British Columbia and Alberta, which was preceded by Lexston's acquisition of all of the issued and outstanding common shares of the Company in exchange for 23,000,000 common shares of Lexston in a reverse take-over transaction.

We consent to being named and to the use in the above-mentioned Prospectus of our report dated February 5, 2021 to the shareholders of the Company on the following financial statements:

- Statement of financial position as at November 30, 2020;
- Statements of operations and comprehensive loss, changes in equity and cash flows for the period from July 1, 2020 (date of incorporation) to November 30, 2020 and related notes to the financial statements including a summary of significant accounting policies.

We report that we have read the Prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the filing statement as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,

SATURNA GROUP CHARTERED PROFESSIONAL ACCOUNTANTS LLP

